2 research outputs found
The use of reverse abdominoplasty for treatment of chemical burn in the thoracoabdominal region
Chemical burn is a challenge owing to its severity compared to thermal burns. The depth and extent of lesions in different areas of the body lead us to look for different possibilities for the best treatment of the patient. A reverse abdominoplasty surgical technique was proposed; this involves a skin flap that could reduce the exposed area of a chemical burn. The result was satisfactory, reducing the patient's treatment, surgical and hospitalization time, highlighting the proposed technique as an important tool for thoracoabdominal reconstruction
Multidrug resistance in chronic myeloid leukaemia: how much can we learn from MDR–CML cell lines?
The hallmark of CML (chronic myeloid leukaemia) is the BCR (breakpoint cluster region)–ABL fusion gene. CML evolves through three phases, based on both clinical and pathological features: a chronic phase, an accelerated phase and blast crisis. TKI (tyrosine kinase inhibitors) are the treatment modality for patients with chronic phase CML. The therapeutic potential of the TKI imatinib is affected by BCR–ABL dependent an independent mechanisms. Development of MDR (multidrug resistance) contributes to the overall clinical resistance. MDR involves overexpression of ABC -transporters (ATP-binding-cassette transporter) among other features. MDR studies include the analysis of cancer cell lines selected for resistance. CML blast crisis is accompanied by increased resistance to apoptosis. This work reviews the role played by the influx transporter OCT1 (organic cation transporter 1), by efflux ABC transporters, molecules involved in the modulation of apoptosis (p53, Bcl-2 family, CD95, IAPs (inhibitors of apoptosis protein)], Hh and Wnt/β-catenin pathways, cytoskeleton abnormalities and other features described in leukaemic cells of clinical samples and CML cell lines. An MDR cell line, Lucena-1, generated from K562 by stepwise exposure to vincristine, was used as our model and some potential anticancer drugs effective against the MDR cell line and patients’ samples are presented